News

Recordati has entered into an agreement with Amdipharm for marketing and sales of TransAct LAT (local action transcutaneous) in Italy and Portugal. Its a transdermal patch containing 40mg

CytRx’ investigational cancer drug, INNO-206 has caused destruction of implanted tumors in an experimental animal model of breast cancer. It performed considerably better than the broadly used chemotherapeutic

Sunesis has received a $1.5 million milestone payment from Biogen Idec for the selection of a Raf kinase inhibitor development candidate. It is intended for the treatment of

Teva Pharmaceutical has received the FDA approval for its New Drug Application (NDA) of Plan B One-Step emergency contraception (levonorgestrel tablet, 1.5mg). With new Plan B One-Step, women

Sirius has signed a collaborative agreement with the Assistance Publique -Hopitaux de Paris (AP-HP), to study genomic co-rrelations in severe sepsis patients. The agreement focuses on the continued

AxoGen is all set to start full distribution of Avance Nerve Graft, human tissue product. It is intended to use in the reconstruction of damaged peripheral nerves for

AMAG has launched Feraheme (ferumoxytol) injection in the US. Feraheme is an intravenous iron replacement therapy, for the treatment of iron deficiency anemia in adult patients with chronic

Elan and Transition Therapeutics has presented phase 1 data, which demonstrated that treatment with ELND005 (scyllo-inositol) has achieved desired concentrations in human brain tissue and cerebrospinal fluid. ELND005

BioMarin has completed patient enrollment for the phase I/II clinical trial of BMN-110 or N-acetylgalactosamine 6-sulfatase (GALNS). The BMN-110 trial is intended for the treatment of the lysosomal